JP2013519683A5 - - Google Patents

Download PDF

Info

Publication number
JP2013519683A5
JP2013519683A5 JP2012553046A JP2012553046A JP2013519683A5 JP 2013519683 A5 JP2013519683 A5 JP 2013519683A5 JP 2012553046 A JP2012553046 A JP 2012553046A JP 2012553046 A JP2012553046 A JP 2012553046A JP 2013519683 A5 JP2013519683 A5 JP 2013519683A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
treatment
pharmaceutically acceptable
composition according
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012553046A
Other languages
English (en)
Japanese (ja)
Other versions
JP5928828B2 (ja
JP2013519683A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/024583 external-priority patent/WO2011100585A1/en
Publication of JP2013519683A publication Critical patent/JP2013519683A/ja
Publication of JP2013519683A5 publication Critical patent/JP2013519683A5/ja
Application granted granted Critical
Publication of JP5928828B2 publication Critical patent/JP5928828B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012553046A 2010-02-11 2011-02-11 Ｎｍｄａ受容体モジュレータを安定化させる二次構造及びその使用 Active JP5928828B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30347210P 2010-02-11 2010-02-11
US61/303,472 2010-02-11
PCT/US2011/024583 WO2011100585A1 (en) 2010-02-11 2011-02-11 Secondary structure stabilized nmda receptor modulators and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016080043A Division JP6328169B2 (ja) 2010-02-11 2016-04-13 Ｎｍｄａ受容体モジュレータを安定化させる化合物及びそれを含む医薬組成物

Publications (3)

Publication Number Publication Date
JP2013519683A JP2013519683A (ja) 2013-05-30
JP2013519683A5 true JP2013519683A5 (enExample) 2014-03-27
JP5928828B2 JP5928828B2 (ja) 2016-06-01

Family

ID=44368160

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2012553046A Active JP5928828B2 (ja) 2010-02-11 2011-02-11 Ｎｍｄａ受容体モジュレータを安定化させる二次構造及びその使用
JP2016080043A Expired - Fee Related JP6328169B2 (ja) 2010-02-11 2016-04-13 Ｎｍｄａ受容体モジュレータを安定化させる化合物及びそれを含む医薬組成物
JP2018079295A Withdrawn JP2018119004A (ja) 2010-02-11 2018-04-17 Ｎｍｄａ受容体モジュレータを安定化させる化合物及びそれを含む医薬組成物
JP2020046041A Pending JP2020117510A (ja) 2010-02-11 2020-03-17 Ｎｍｄａ受容体モジュレータを安定化させる化合物及びそれを含む医薬組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016080043A Expired - Fee Related JP6328169B2 (ja) 2010-02-11 2016-04-13 Ｎｍｄａ受容体モジュレータを安定化させる化合物及びそれを含む医薬組成物
JP2018079295A Withdrawn JP2018119004A (ja) 2010-02-11 2018-04-17 Ｎｍｄａ受容体モジュレータを安定化させる化合物及びそれを含む医薬組成物
JP2020046041A Pending JP2020117510A (ja) 2010-02-11 2020-03-17 Ｎｍｄａ受容体モジュレータを安定化させる化合物及びそれを含む医薬組成物

Country Status (13)

Country Link
US (2) US9101612B2 (enExample)
EP (1) EP2542254B1 (enExample)
JP (4) JP5928828B2 (enExample)
CN (2) CN105037492A (enExample)
AU (1) AU2011215704B2 (enExample)
BR (1) BR112012020142A2 (enExample)
CA (1) CA2789331C (enExample)
ES (1) ES2706063T3 (enExample)
IL (1) IL221400A (enExample)
MX (1) MX2012009388A (enExample)
RU (1) RU2566821C2 (enExample)
SG (3) SG10201501050RA (enExample)
WO (1) WO2011100585A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0918868B8 (pt) 2008-09-18 2021-05-25 Naurex Inc compostos moduladores do receptor de nmda e composições compreendendo os mesmos
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
US9101612B2 (en) * 2010-02-11 2015-08-11 Northwestern University Secondary structure stabilized NMDA receptor modulators and uses thereof
KR101692275B1 (ko) * 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
EA032153B1 (ru) * 2013-01-29 2019-04-30 Аптиникс Инк. Спиролактамные модуляторы nmda-рецептора и их применение
KR20150110784A (ko) 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
AU2014212484B2 (en) 2013-01-29 2018-01-04 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam NMDA receptor modulators and uses thereof
PE20151438A1 (es) * 2013-01-29 2015-10-10 Naurex Inc Moduladores de receptores nmda de espiro-lactama y sus usos
AU2014212487C1 (en) * 2013-01-29 2018-10-25 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
SG10201810496XA (en) * 2013-10-28 2018-12-28 Naurex Inc Nmda receptor modulators and prodrugs, salts, and uses thereof
CN112716890A (zh) * 2014-04-25 2021-04-30 诺雷克斯股份有限公司 神经活性肽的稳定组合物
KR20170018072A (ko) * 2014-06-23 2017-02-15 노오쓰웨스턴 유니버시티 편두통을 치료 또는 경감시키는 방법
WO2016014982A1 (en) * 2014-07-24 2016-01-28 Naurex, Inc. N-methyl-d-aspartate receptor modulators and methods of making and using same
AU2016340239A1 (en) * 2015-10-14 2018-05-31 Bristol-Myers Squibb Company Selective NR2B antagonists
BR112018006537A2 (pt) 2015-10-14 2018-10-16 Bristol-Myers Squibb Company antagonistas seletivos de nr2b
AU2016340080A1 (en) * 2015-10-16 2018-05-10 Northwestern University Pharmaceutical combination of an atypical antipsychotic and an NMDA modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder
US20210198315A1 (en) * 2016-02-01 2021-07-01 Naurex, INC Process for synthesis of peptide compounds
PE20190174A1 (es) 2016-05-19 2019-02-01 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20190504A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos
EP3490992B1 (en) 2016-08-01 2023-03-22 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
SG11201900558RA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
EA201990425A1 (ru) 2016-08-01 2019-08-30 Аптиникс Инк. Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение
CN109843889B (zh) 2016-08-01 2022-03-15 阿普廷伊克斯股份有限公司 螺-内酰胺nmda调节剂和使用其的方法
CN112218866A (zh) * 2018-01-31 2021-01-12 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
CA3089561A1 (en) 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CN113480596A (zh) * 2019-04-09 2021-10-08 北京广为医药科技有限公司 一种调节nmda受体活性的化合物、其药物组合物及用途
EP4007574A4 (en) * 2019-08-01 2023-08-02 Aptinyx Inc. METHODS OF TREATMENT OF DISEASES ASSOCIATED WITH INCREASED LEVELS OF ANTIBODIES THAT INTERACT WITH THE NMDA RECEPTOR
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
CN114957444B (zh) * 2022-05-31 2023-09-19 陕西脉元生物科技有限公司 一种nmdar的nr1亚基缺失突变体、突变体细胞及构建方法和应用
CN114957445B (zh) * 2022-05-31 2023-09-19 陕西脉元生物科技有限公司 一种nmdar nr1亚基、nmdar的突变体及其构建方法和应用

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683221A (en) 1986-01-09 1987-07-28 Scripps Clinic And Research Foundation Lymphocyte-activating polypeptides
CA1305177C (en) 1987-06-30 1992-07-14 Yasufumi Ohfune Carboxycyclopropylglycine and process for producing the same
US4904681A (en) 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
EP0360390A1 (en) 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
US5061721A (en) 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5086072A (en) 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
WO1992007561A1 (en) 1990-10-30 1992-05-14 Ss Pharmaceutical Co., Ltd. Antiphlogistic and analgesic gel preparation
JP3318622B2 (ja) 1992-05-27 2002-08-26 独立行政法人産業技術総合研究所 プロリルエンドペプチダーゼ阻害剤
FR2692268B1 (fr) 1992-06-15 1994-08-19 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activité de récepteur NMDA, acides nucléiques codant pour ces polypeptides et utilisations.
SE9301667D0 (sv) 1993-05-14 1993-05-14 Kabi Pharmacia Ab New use
US5523323A (en) 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
US5605911A (en) 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US5741778A (en) 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
US6541453B2 (en) 1996-06-07 2003-04-01 Syngenta Limited Peptide derivatives
EP0918859A1 (en) 1996-08-02 1999-06-02 ZymoGenetics, Inc. Testis-specific insulin homolog polypeptides
US5902815A (en) 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
JP3955345B2 (ja) 1996-09-27 2007-08-08 サントリー株式会社 新規アミノ酸ダイジハーベイン
EP0990051A1 (en) * 1997-07-07 2000-04-05 Florida State University Identification of molecular targets
US6897028B1 (en) 1997-07-07 2005-05-24 Florida State University Identification of molecular targets
WO1999024584A1 (en) 1997-11-12 1999-05-20 Neurotherapeutics Methods for the detection and treatment of disease using a glycosyltransferase
US5952389A (en) 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
US6274314B1 (en) 1998-04-02 2001-08-14 Nyxis Neurotherapies, Inc. Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine
US6197820B1 (en) 1998-04-06 2001-03-06 Uab Research Foundation Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions
US6025471A (en) 1998-06-03 2000-02-15 Deghenghi; Romano Diazaspiro, azepino and azabicyclo therapeutic peptides
US6902886B1 (en) 1998-11-06 2005-06-07 The Research Foundation Of State University Of New York Genetic assay for protein nuclear transport
US6194158B1 (en) 1998-11-12 2001-02-27 Nyxis Neurotherapies, Inc. Diagnostic assay for cancer
US20030064921A1 (en) 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
WO2001036685A2 (en) 1999-11-17 2001-05-25 Nyxis Neurotherapies, Inc. Differential gene expression in cancer
WO2001057240A2 (en) 2000-02-01 2001-08-09 Agy Therapeutics, Inc. Interaction of nmda receptor with protein tyrosine phosphatase
WO2001096606A2 (en) 2000-06-14 2001-12-20 Nyxis Neurotherapies, Inc. Identification of genes and compounds for treatment of cancer
WO2001098367A2 (en) 2000-06-22 2001-12-27 Nyxis Neurotherapies, Inc. Neuroactive peptides for treatment of hypoxia and related conditions
IL145209A0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
EP1186303A3 (en) 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
UA73619C2 (en) 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
US20020142287A1 (en) 2000-12-14 2002-10-03 Hirotaka Yamamoto High throughput assay to detect inhibitors of the map kinase pathway
US20030065138A1 (en) 2001-03-07 2003-04-03 University Of Utah Research Foundation Linear gamma-carboxyglutamate rich conotoxins
AU2002255705A1 (en) 2001-03-12 2002-09-24 Nyxis Neurotherapies, Inc Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
US7863304B2 (en) 2001-05-24 2011-01-04 Neuren Pharmaceuticals Limited Analogs of glycyl-prolyl-glutamate
MXPA03010762A (es) 2001-05-31 2005-03-07 Univ Princeton Peptidos enlazantes de iap y ensayos para identificar los compuestos que enlazan el iap.
US20030022253A1 (en) * 2001-07-25 2003-01-30 Nyxis Neurotherapies, Inc. Method for identifying, isolating and producing neuroactive binding agents and binding agents derived thereby
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
WO2005014797A2 (en) 2003-08-08 2005-02-17 The Burnham Institute P16 mediated regulation of nmda receptors
WO2005020973A2 (en) 2003-08-29 2005-03-10 The University Of Houston System Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxylamine
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
US7951912B2 (en) 2005-08-26 2011-05-31 Wisconsin Alumni Research Foundation Poly-β-peptides from functionalized β-lactam monomers and antibacterial compositions containing same
US8507439B2 (en) * 2005-08-29 2013-08-13 Angela Shashoua Neuroprotective and neurorestorative method and compositions
US20070208001A1 (en) 2006-03-03 2007-09-06 Jincong Zhuo Modulators of 11- beta hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
MX2009002921A (es) 2006-09-15 2009-04-01 Schering Corp Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico.
CN101066945B (zh) 2007-05-25 2010-05-19 中国科学院上海有机化学研究所 一种合成3-位取代内酰胺类化合物的方法
CN101125817B (zh) 2007-08-03 2011-09-14 中国科学院上海有机化学研究所 一种合成高对映选择性醛基取代小环胺类化合物和光学活性3-位取代内酰胺类化合物的方法
WO2009039390A2 (en) 2007-09-20 2009-03-26 Naurex Inc. The development of glycobiology-based therapeutics for the treatment of brain tumors
BRPI0916609A2 (pt) 2008-08-07 2015-08-04 Hoffmann La Roche Processo para a preparação de um macrociclo
BRPI0918868B8 (pt) * 2008-09-18 2021-05-25 Naurex Inc compostos moduladores do receptor de nmda e composições compreendendo os mesmos
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
CN102316886B (zh) 2008-12-15 2014-06-18 可尔必思株式会社 抗皮肤老化肽
WO2011003064A2 (en) 2009-07-02 2011-01-06 Naurex, Inc. Methods of treating neuropathic pain
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
EP2485751B1 (en) 2009-10-05 2014-05-21 Northwestern University GLYX-13 for use in a method of treating refractory depression
EA022494B1 (ru) * 2009-12-17 2016-01-29 Мерк Шарп Энд Домэ Корп. Соединения хинолинамида в качестве положительных аллостерических модуляторов мускаринового рецептора m1
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
US9101612B2 (en) * 2010-02-11 2015-08-11 Northwestern University Secondary structure stabilized NMDA receptor modulators and uses thereof
KR20210046843A (ko) 2011-04-27 2021-04-28 노오쓰웨스턴 유니버시티 알츠하이머병, 헌팅톤병, 자폐증 또는 기타 장애의 치료 방법
US8795919B2 (en) 2011-11-29 2014-08-05 Societe BIC & Sanyo Electric Co., Ltd. Fuel cell layer

Similar Documents

Publication Publication Date Title
JP2013519683A5 (enExample)
JP2015501783A5 (enExample)
JP2013032389A5 (enExample)
JP2013530958A5 (enExample)
JP2013532687A5 (enExample)
JP2015504870A5 (enExample)
CO6531458A2 (es) Nuevos compuestos de espiropiperidina
NO343929B3 (no) 1-[2-(2,4-dimetylfenylsulfanyl-fenyl]-piperazin som en forbindelse med kombinert serotoninreopptak, 5-HT3- og 5HT1A-aktivitet for behandlingen av kognitiv smerte
JP2011168603A5 (enExample)
ES2723277T3 (es) Una forma sólida de clorhidrato de (S)-3-(4-((4-morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona
JP2012072162A5 (enExample)
AR087451A1 (es) Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
JP2011105738A5 (enExample)
ECSP12011930A (es) Nuevos compuestos de espiropiperidina
JP2013525444A5 (enExample)
JP2015503422A5 (enExample)
JP2011518833A5 (enExample)
EP2484673A3 (en) A process for the resolution of (R,S)-nicotine
ES2560676T3 (es) Combinación farmacéutica para el tratamiento del dolor
CY1118662T1 (el) Νεες δικυκλικες πυριδινονες
EA201590735A1 (ru) 2-фенил-5-гетероциклил-тетрагидро-2h-пиран-3-аминовые соединения для применения в лечении диабета и связанных с ним расстройств
JP2012519182A5 (enExample)
IN2015DN00845A (enExample)
EA201792597A2 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
CL2012000263A1 (es) Compuestos derivados de amidas espiro ciclica, agonista b-adrenoreceptor y antagonista muscarinico; utiles en el tratamiento en enfermedades inflamatorias, tales como epoc.